Research programme: androgen receptor antagonists - Janssen Research & Development

Drug Profile

Research programme: androgen receptor antagonists - Janssen Research & Development

Alternative Names: SARD programme - Aragon Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California System
  • Developer Janssen Research & Development
  • Class Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Prostate-cancer(Hormone refractory) in USA (PO)
  • 19 Aug 2013 Aragon Pharmaceuticals has been acquired and merged into Johnson & Johnson
  • 01 Oct 2012 Early research in Prostate cancer (hormone refractory) is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top